China demand volatility
A large portion of sales is tied to APAC, and China sales have shown sharp swings in reported periods.
- Scope
- APAC revenue and global growth rate
- Materiality
- high
STAAR Surgical Company
STAAR Surgical designs, manufactures, and sells implantable lenses for the eye and the accessory delivery systems used to place them. Its core business centers on Collamer® implantable collamer lenses (ICLs), which are used in refractive eye surgery and sold across the Americas, Europe, the Middle East, Africa, and Asia-Pacific.
−34,8 %
76,2 %
−33,6 %
4.55
4.55
| % | |
|---|---|
| Implantable Collamer® lenses (ICLs) | 90% Phakic implantable lenses used in refractive surgery to correct vision without removing the natural lens. |
| Accessory delivery systems | 10% Devices and tools used by surgeons to deliver ICLs into the eye during procedures. |
Customers are ophthalmic surgeons, refractive surgery centers, and eye-care providers that perform elective...
- Refractive surgeons and surgical centersprimary
Buy ICLs and delivery systems for elective refractive procedures and value predictable surgical workflow.
- International distributorsprimary
Purchase and distribute ICL products in markets served through channel partners.
- Ophthalmology clinicssecondary
Use the lenses in vision-correction procedures and rely on surgeon education and support.
- Patients seeking refractive correctionsecondary
End users who choose ICL procedures for visual freedom and reversible lens implantation.
STAAR sells worldwide, with business concentrated in Asia-Pacific, EMEA, and the Americas...
- •APAC is a major sales region and includes China, Japan, Korea, and India
- •EMEA includes both distributor and direct markets
- •The Americas include the U.S., Canada, and Latin America distributors
- •China is an important market and can drive quarter-to-quarter swings
- •Foreign currency movements affect reported sales and comparability
STAAR’s strategy is to expand the availability of its full ICL product line in existing markets while entering...
01
Broaden market access for the ICL portfoliomedium-term
A wider product footprint increases procedure adoption and deepens penetration in served markets.
02
Build surgeon awareness and trainingshort-term
ICL adoption depends on surgeon familiarity, procedural confidence, and patient education.
03
Support sustainable commercializationmedium-term
The business relies on recurring procedure volume and distributor/surgeon engagement across regions.
STAAR is exposed to demand concentration in refractive surgery markets, especially China and other APAC countries,...
Merger-related transaction risk
The filing describes stockholder approval, litigation, and regulatory conditions that may not be satisfied.
- Scope
- Corporate transaction process
- Materiality
- high
Market adoption and surgeon education risk
ICL procedures require surgeon familiarity and patient acceptance to expand volume.
- Scope
- Newer markets and product penetration
- Materiality
- high
Distributor/channel execution risk
International sales rely partly on distributor markets, which can affect inventory, sell-through, and pricing.
- Scope
- EMEA and APAC distributor markets
- Materiality
- medium
Foreign exchange exposure
Global sales create translation and transaction exposure across multiple currencies.
- Scope
- Reported revenue and margins
- Materiality
- medium
Revenue recognition and sales return allowances
Quarterly revenue comparability
Restructuring and impairment charges
Operating expense and asset carrying values
Lease accounting and right-of-use assets
Balance sheet and expense recognition
Foreign currency effects
Reported revenue and other income
: 29.4.2026